Segall Bryant & Hamill LLC Has $19.26 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Segall Bryant & Hamill LLC cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.0% in the first quarter, Holdings Channel reports. The firm owned 298,056 shares of the biopharmaceutical company’s stock after selling 9,168 shares during the period. Segall Bryant & Hamill LLC’s holdings in Halozyme Therapeutics were worth $19,263,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Abel Hall LLC increased its holdings in Halozyme Therapeutics by 4.2% in the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 129 shares during the last quarter. StoneX Group Inc. increased its holdings in Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after buying an additional 132 shares during the last quarter. Moran Wealth Management LLC raised its position in Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after acquiring an additional 151 shares in the last quarter. Finally, Twin Capital Management Inc. raised its position in Halozyme Therapeutics by 1.4% during the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 161 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. The trade was a 3.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This represents a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock worth $5,102,643 in the last ninety days. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $82.54 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $58.53 and a twelve month high of $84.44. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $9.79 billion, a PE ratio of 29.69, a P/E/G ratio of 0.34 and a beta of 0.84. The stock has a 50-day simple moving average of $74.52 and a 200 day simple moving average of $70.93.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue was up 42.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on HALO shares. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.